Europe
London-based Clinigen Group pc will now have full rights to Proleukin (aldesleukin, human recombinant interleukin-2). This morning, the U.K.-based pharmaceutical and services company struck a deal with Novartis to acquire the U.S. rights to the metastatic renal cell carcinoma treatment.
Adocia announced that four abstracts featuring its BioChaperone® technology have been accepted for presentation at the 12th International Conference on Advanced Technologies & Treatments for Diabetes being held February 20-23, 2019 in Berlin, Germany.
Researchers in the School of Pharmacy at the University of Nottingham have been using Dolomite Microfluidic’s chips to enhance their work on drug encapsulation and therapeutic delivery.
Request and task management software increases operational efficiency of biopharma R&D organizations
Estimated enterprise value of EUR 160 million compared to current EV of EUR 121 million
Recipharm, the contract development and manufacturing organisation, has appointed a new director of business management for the USA and Canada to accelerate growth in the region.
Karolinska Development’s portfolio company OssDsign announces today the closing of a private placement of SEK 64 million.
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.
The company, developing innovative, minimally invasive medical devices for gastroenterologists, also welcomes Denis Gestin as new chairman of the board
PRESS RELEASES